Lexeo Therapeutics Names Tim Van Hauwermeiren to Board

NEW YORK, July 08, 2024 – LEXEO Therapeutics Inc. (Nasdaq: LXEO), a clinical-stage genetic medicine company, announced that Tim Van Hauwermeiren, co-founder and CEO of argenx SE, has been appointed as an independent, non-executive director on its Board of Directors. Van Hauwermeiren brings over twenty years of experience in management and business development within the life sciences and consumer goods sectors.

R. Nolan Townsend, CEO of Lexeo Therapeutics, expressed his enthusiasm about the appointment, highlighting Van Hauwermeiren's extensive experience in building biotech companies from clinical stages to commercial success. Townsend believes Van Hauwermeiren's expertise will be crucial as Lexeo advances its pipeline into more developed clinical and commercial phases.

Van Hauwermeiren is a prominent figure in the biotech industry, having co-founded argenx, a global immunology company valued at nearly $25 billion. At argenx, he led the development and market introduction of efgartigimod, a treatment for severe autoimmune diseases. He has also significantly expanded the company’s presence in Europe, the U.S., and Asia, and secured over $4 billion in funding through equity raises and strategic transactions with major pharmaceutical firms. Before establishing argenx, Van Hauwermeiren held roles at Ablynx and Procter & Gamble, gradually taking on more responsibility.

Expressing his honor to join Lexeo’s Board, Van Hauwermeiren praised the company’s innovative science and ambitious vision. He is eager to contribute his knowledge and experience to help Lexeo bring transformative therapies to patients suffering from serious genetic diseases.

Van Hauwermeiren also serves on the Board of Directors of iTeos Pharmaceuticals and previously served on the Board of RayzeBio before its acquisition by Bristol Myers Squibb. He holds a B.Sc. and M.Sc. in bioengineering from Ghent University and an Executive MBA from The Vlerick School of Management.

Lexeo Therapeutics, based in New York City, is a clinical-stage company focused on genetic medicine. Their mission is to revolutionize healthcare by applying cutting-edge science to treat genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease. Leveraging early proof-of-concept data, Lexeo is advancing its pipeline of treatments through a methodical development process aimed at bringing significant improvements to patient care.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!